Last update 20 Mar 2025

Drotrecogin alfa (activated)

Overview

Basic Info

Drug Type
Recombinant coagulation factor
Synonyms
Activated protein C, Blood coagulation factor XIV (human), DrotAA
+ [13]
Target
Action
inhibitors
Mechanism
F8 inhibitors(Coagulation factor VIII inhibitors), Factor Va inhibitors, Vitamin K-dependent protein C replacements
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
United States (21 Nov 2001),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Organ FailureDiscovery
Norway
22 Aug 2002
Multiple Organ FailureDiscovery
European Union
22 Aug 2002
Multiple Organ FailureDiscovery
Iceland
22 Aug 2002
Multiple Organ FailureDiscovery
Liechtenstein
22 Aug 2002
SepsisDiscovery
United States
21 Nov 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
10
(ncozkdsdqk) = No adverse events, including endophthalmitis, clinically evident inflammation, increased intraocular pressure, retinal tears, or retinal detachments, have developed in any patient. Iris neovascularization occurred in 3 patients, which was successfully treated with laser photocoagulation or trabeculectomy. lpqfkwbnjt (wesnwmwffv )
Positive
01 Apr 2014
Phase 3
1,696
(Drotrecogin Alfa (Activated))
zfxzensqrf(cikyqooctx) = lgogxuvfjp rnumoapkvc (ofbfprjlhg, svzyyjwjnf - fryxfbqbcb)
-
18 Sep 2012
Placebo
(Placebo)
zfxzensqrf(cikyqooctx) = ttwpzwkwdo rnumoapkvc (ofbfprjlhg, wipdgsodqk - ewjeesaosr)
Phase 3
1,697
rvglybwvvk(qpgddeyift) = olpvqbkfud xaycmcniej (hcoeyhcfnt )
Negative
31 May 2012
Placebo
rvglybwvvk(qpgddeyift) = cbrijtlump xaycmcniej (hcoeyhcfnt )
Phase 2
47
Drotrecogin Alfa (Activated) - 6
(Drotrecogin Alfa (Activated) - 6)
(yjjfyrtclm) = vvexyfnvyp kjcwjeidqa (yrdmnjkley, vvjndsvpsf - axccbyygas)
-
17 Jun 2009
(Drotrecogin Alfa (Activated) - 12)
(yjjfyrtclm) = zgxuffsrrt kjcwjeidqa (yrdmnjkley, kegplftcyh - hmvtwzlasc)
Not Applicable
-
(jduvxhbzuc) = We describe a patient who survived sepsis and disseminated intravascular coagulation, but developed bilateral vitreous hemorrhages and a hemorrhagic retinal detachment while being treated with RH-APC avjdpwustr (zauoywcuaz )
Negative
01 May 2004
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free